PPPhuc Tuong Pham

Phuc Tuong Pham

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Phuc Tuong Pham has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Early Magnesium Sulfate Administration and Mortality in Critically Ill Patients with Pneumonia: A Retrospective Analysis of the MIMIC-IV Database

    by Thanh Luan Nguyen, Hoang Ngoc Thao Duong, Thi Bao Yen Nguyen, Quang Dai Le, Phan Ngoc An Huynh, Van Hoang Nam Ho, Cong Dang Tran, Phuc Tuong Pham, Trang Nguyen Hoai Dinh, Van Phieu Duong

    Background: Disturbances in magnesium homeostasis and magnesium supplementation are common in critical illness; however, the association between early intravenous magnesium sulfate administration and clinical outcomes in critically ill patients with pneumonia remains unclear. Methods: This retrospective observational cohort study used data from the Medical Information Mart for Intensive Care IV (version 3.1) database and included critically ill patients admitted to the intensive care unit (ICU) with pneumonia. Patients were classified according to early exposure to intravenous magnesium sulfate, defined as administration from 6 h before to 24 h after ICU admission, or no exposure during this period. The primary outcome was 30-day all-cause mortality, with secondary outcomes including 60-day and 90-day mortality. Associations were evaluated using multivariable Cox proportional hazards models, with prespecified subgroup, interaction, and sensitivity analyses, including propensity score matching. Results: Among 9203 eligible patients, 2975 (32.3%) received early intravenous magnesium sulfate. Magnesium sulfate administration was associated with lower 30-day mortality after multivariable adjustment (adjusted hazard ratio [aHR] 0.84; 95% confidence interval [CI] 0.76-0.94; p = .002). Similar associations were observed for 60-day mortality (aHR 0.86; 95% CI 0.78-0.95; p = .002) and 90-day mortality (aHR 0.87; 95% CI 0.80-0.96; p = .004). Subgroup analysis identified a significant interaction for sepsis status (p for interaction = .007). In a propensity score–matched cohort, magnesium sulfate administration remained associated with lower 30-day mortality (aHR 0.85; 95% CI 0.74-0.96; p = .012). Conclusions: In critically ill patients with pneumonia, early intravenous magnesium sulfate administration was associated with lower mortality. These findings are hypothesis-generating and suggest the need for prospective studies to clarify causality and define optimal dosing and duration of magnesium supplementation in this population.


  • Association between the Modified NUTRIC Score (mNUTRIC) and Clinical Outcomes in a Mixed Intensive Care Unit: A Retrospective Cohort Study

    by Thanh Luan Nguyen, Quang Dai Le, Trang Nguyen Hoai Dinh, Van Hoang Nam Ho, Cong Dang Tran, Van Phieu Duong, Hoang Ngoc Thao Duong, Phuc Tuong Pham, Thi Phuong Thao Le, Tuyet Phuong Bui


  • Open Access

    Rethinking hypomagnesemia: diagnostic thresholds and metabolic implications in critical illness

    by Thanh Luan Nguyen, Van Phieu Duong, Hoang Ngoc Thao Duong, Phuc Tuong Pham, Van Hoang Nam Ho, Quang Dai Le, Cong Dang Tran


  • Open Access

    Corticosteroids in non-viral acute respiratory distress syndrome (ARDS): recommendations outpace evidence – a concise review

    by Thanh Luan Nguyen, Phuc Tuong Pham, Van Phieu Duong, Hoang Ngoc Thao Duong

    The 2024 global redefinition of acute respiratory distress syndrome (ARDS) broadens diagnostic criteria to include patients on non-invasive respiratory support. While this inclusivity enhances early recognition, it also introduces heterogeneity in disease severity, inflammatory burden, and treatment responsiveness–complicating the use of corticosteroids. Although recent guidelines recommend corticosteroids for moderate-to-severe ARDS, they fall short of specifying optimal timing, dosing, and patient selection. The DEXA-ARDS trial showed that high-dose dexamethasone reduced mortality in moderate-to-severe ARDS regardless of etiology, but its generalizability to less severe or non-intubated patients remains unclear. Conversely, in severe community-acquired pneumonia (CAP), hydrocortisone regimens used in CAPE-COD and APROCCHSS trials demonstrated mortality benefits, suggesting a particular therapeutic niche for corticosteroids in non-viral, infection-associated ARDS. A recent network meta-analysis suggests that low-dose methylprednisolone may reduce ARDS mortality, though phenotype-specific efficacy is not well defined. Despite these encouraging signals, key questions persist: Which corticosteroid? At what dose? For which ARDS phenotype? As evidence accumulates unevenly across ARDS subtypes, guideline-endorsed recommendations may inadvertently mask the nuances required for individualized therapy. Until precision approaches are better defined, clinicians must balance empirical benefit with thoughtful restraint in applying corticosteroids to non-viral ARDS. This concise review summarizes current evidence, key limitations, and pragmatic phenotype-informed strategies for corticosteroid use in non-viral ARDS.